JP2024539852A5 - - Google Patents
Info
- Publication number
- JP2024539852A5 JP2024539852A5 JP2024521120A JP2024521120A JP2024539852A5 JP 2024539852 A5 JP2024539852 A5 JP 2024539852A5 JP 2024521120 A JP2024521120 A JP 2024521120A JP 2024521120 A JP2024521120 A JP 2024521120A JP 2024539852 A5 JP2024539852 A5 JP 2024539852A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitors
- degraders
- compound
- cancer
- mek
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21206336.6 | 2021-11-04 | ||
| EP21206336 | 2021-11-04 | ||
| PCT/EP2022/080475 WO2023078881A1 (en) | 2021-11-04 | 2022-11-02 | Novel use of quinazolinone compound for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024539852A JP2024539852A (ja) | 2024-10-31 |
| JP2024539852A5 true JP2024539852A5 (enExample) | 2025-11-11 |
Family
ID=78516703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024521120A Pending JP2024539852A (ja) | 2021-11-04 | 2022-11-02 | がんの治療のためのキナゾリノン化合物の新規使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240366605A1 (enExample) |
| EP (1) | EP4426305A1 (enExample) |
| JP (1) | JP2024539852A (enExample) |
| KR (1) | KR20240105382A (enExample) |
| CN (1) | CN118201615A (enExample) |
| AU (1) | AU2022383040A1 (enExample) |
| CA (1) | CA3230652A1 (enExample) |
| IL (1) | IL312171A (enExample) |
| MX (1) | MX2024005107A (enExample) |
| TW (1) | TW202333707A (enExample) |
| WO (1) | WO2023078881A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| MX2023014059A (es) | 2021-06-08 | 2024-03-12 | C4 Therapeutics Inc | Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante. |
| WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| EP4618994A1 (en) * | 2022-11-18 | 2025-09-24 | F. Hoffmann-La Roche AG | Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases |
| WO2024126660A1 (en) * | 2022-12-15 | 2024-06-20 | F. Hoffmann-La Roche Ag | Combination therapy for cancer treatment |
| WO2025261943A1 (en) * | 2024-06-18 | 2025-12-26 | F. Hoffmann-La Roche Ag | Anti-cancer combinations comprising mosperafenib and folfox or folfiri |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100984595B1 (ko) | 2002-03-13 | 2010-09-30 | 어레이 바이오파마 인크. | Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체 |
| SI1934174T1 (sl) | 2005-10-07 | 2011-08-31 | Exelixis Inc | Inhibitorji MEK in postopki za njihovo uporabo |
| WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| ES2699351T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| TW201930292A (zh) | 2017-10-12 | 2019-08-01 | 美商銳新醫藥公司 | 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物 |
| TWI817018B (zh) * | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| PH12022551119A1 (en) | 2019-12-10 | 2023-08-23 | Hoffmann La Roche | New methylquinazolinone derivatives |
| IL307964A (en) * | 2021-06-09 | 2023-12-01 | Chugai Pharmaceutical Co Ltd | Combined treatment for cancer |
| CA3216220A1 (en) * | 2021-06-09 | 2022-12-15 | F. Hoffmann-La Roche Ag | Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer |
-
2022
- 2022-11-02 EP EP22814296.4A patent/EP4426305A1/en active Pending
- 2022-11-02 IL IL312171A patent/IL312171A/en unknown
- 2022-11-02 KR KR1020247014717A patent/KR20240105382A/ko active Pending
- 2022-11-02 MX MX2024005107A patent/MX2024005107A/es unknown
- 2022-11-02 JP JP2024521120A patent/JP2024539852A/ja active Pending
- 2022-11-02 CA CA3230652A patent/CA3230652A1/en active Pending
- 2022-11-02 WO PCT/EP2022/080475 patent/WO2023078881A1/en not_active Ceased
- 2022-11-02 CN CN202280073254.9A patent/CN118201615A/zh active Pending
- 2022-11-02 AU AU2022383040A patent/AU2022383040A1/en active Pending
- 2022-11-03 TW TW111142082A patent/TW202333707A/zh unknown
-
2024
- 2024-05-03 US US18/653,975 patent/US20240366605A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024539852A5 (enExample) | ||
| MX2022015695A (es) | Medicina de camptotecina con alta unidad de conexion hidrofila y conjugado de la misma. | |
| TWI599369B (zh) | 包含阿柏西普（ａｆｌｉｂｅｒｃｅｐｔ）、醛葉酸、５－氟尿嘧啶（５－ｆｕ）及伊立替康（ｉｒｉｎｏｔｅｃａｎ）（ｆｏｌｆｉｒｉ）之組合物 | |
| JP2019530752A (ja) | がんを治療するための薬物の調製における、抗ｐｄ‐１抗体とｖｅｇｆｒ阻害剤とを組み合わせた使用 | |
| JP2025511399A5 (enExample) | ||
| KR20060054412A (ko) | 암 치료 및 억제용 표피 성장인자 수용체 키나제 억제제와세포독성제의 배합물 용도 | |
| MX2007004549A (es) | Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico. | |
| MXPA03010121A (es) | Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales. | |
| JP2017505321A5 (enExample) | ||
| JP6410795B2 (ja) | カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物 | |
| JP2021520406A5 (enExample) | ||
| JP2010043114A (ja) | 腫瘍転移および癌の治療 | |
| JP2018525358A5 (enExample) | ||
| JP2020523354A5 (enExample) | ||
| JP2017214420A (ja) | 樹状細胞癌ワクチンのための小分子エンハンサー | |
| JP2019506392A5 (enExample) | ||
| JP2023524789A5 (enExample) | ||
| JP2024524461A5 (enExample) | ||
| Punt | New drugs in the treatment of colorectal carcinoma | |
| JP2023505687A5 (enExample) | ||
| Legha et al. | Phase I study of spirogermanium given daily. | |
| TW200603804A (en) | Treatment with irinotecan (cpt-11) and an EGFR-inhibitor | |
| CA2483826A1 (en) | Epothilone derivative for the treatment of hepatoma and other cancer diseases | |
| MX2024006168A (es) | Composicion farmaceutica y uso de la misma. | |
| JP2006528696A (ja) | 抗癌剤の抗腫瘍活性を増強する方法 |